169 related articles for article (PubMed ID: 1127095)
1. Elevtion of serum testosterone in ovarian hyperstimulation syndrome.
Schumert Z; Spitz I; Diamant Y; Polishuk WZ; Rabinowitz D
J Clin Endocrinol Metab; 1975 May; 40(5):889-92. PubMed ID: 1127095
[TBL] [Abstract][Full Text] [Related]
2. Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis.
Haning RV; Austin CW; Carlson IH; Kuzma DL; Zweibel WJ
Obstet Gynecol; 1985 Feb; 65(2):199-205. PubMed ID: 3155830
[TBL] [Abstract][Full Text] [Related]
3. Ovarian stimulation during gonadotropin treatment after hCG administration monitored by ultrasound and serum estradiol and progesterone.
Ylöstalo P; Siegberg R
Int J Fertil; 1988; 33(4):259-64. PubMed ID: 2902041
[TBL] [Abstract][Full Text] [Related]
4. Plasma prolactin, human chorionic gonadotropin, estradiol, testosterone, and progesterone in the ovarian hyperstimulation syndrome.
Yuen BH; McComb P; Sy L; Lewis J; Cannon W
Am J Obstet Gynecol; 1979 Feb; 133(3):316-20. PubMed ID: 433993
[TBL] [Abstract][Full Text] [Related]
5. Plasma hormones in human gonadotropin induced ovulation.
Wu CH
Obstet Gynecol; 1977 Mar; 49(3):308-13. PubMed ID: 840459
[TBL] [Abstract][Full Text] [Related]
6. Ovulation induction in polycystic ovary syndrome with urinary follicle-stimulating hormone or human menopausal gonadotropin.
Seibel MM; McArdle C; Smith D; Taymor ML
Fertil Steril; 1985 May; 43(5):703-8. PubMed ID: 3922800
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of follicle-stimulating hormone and human menopausal gonadotropin on peripheral serum and follicular fluid hormones during ovarian stimulation.
Martikainen H; Rönnberg L; Puistola U; Kirkinen P; Ruokonen A; Nikula H; Huhtaniemi I
Fertil Steril; 1986 Aug; 46(2):317-20. PubMed ID: 3089844
[No Abstract] [Full Text] [Related]
8. Human menopausal gonadotropin/human chorionic gonadotropin-induced ovarian hyperstimulation with transient hyperprolactinemia: steroidogenesis enhanced during bromocriptine therapy in monkeys.
Collins RL; Williams RF; Hodgen GD
J Clin Endocrinol Metab; 1984 Oct; 59(4):727-33. PubMed ID: 6434577
[TBL] [Abstract][Full Text] [Related]
9. Ovulation induction with low doses of "pure" follicle stimulating hormone using a fixed protocol in patients with polycystic ovarian disease.
Bregieiro LO; de Moura MD; Ferriani RA; Bailão LA; de Sá MF
Int J Fertil Menopausal Stud; 1993; 38(3):152-9. PubMed ID: 8348163
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
11. [A case of secondary amenorrhea 2nd grade with interesting clinical features (author's transl)].
Kusuda M; Kumamoto H; Nagata Y; Kurano A; Nakamura M
Nihon Funin Gakkai Zasshi; 1974 Jul; 19(3):33-40. PubMed ID: 4478820
[No Abstract] [Full Text] [Related]
12. Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome.
Piltonen T; Koivunen R; Perheentupa A; Morin-Papunen L; Ruokonen A; Tapanainen JS
J Clin Endocrinol Metab; 2004 Aug; 89(8):3769-75. PubMed ID: 15292303
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of the ovarian hyperstimulation syndrome.
Haning RV; Strawn EY; Nolten WE
Obstet Gynecol; 1985 Aug; 66(2):220-4. PubMed ID: 3927208
[TBL] [Abstract][Full Text] [Related]
14. [HMG-HCG therapy for ovarian hyperstimulation syndrome].
Ishimaru T; Okamoto J; Morizaki M; Kajimura H; Nakano T
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jun; 36(6):969-72. PubMed ID: 6431038
[No Abstract] [Full Text] [Related]
15. Side effects of ovarian hyperstimulation: hormonal and lipid profile changes.
Tadmor OP; Kleinman Y; Barr I; Gal M; Brooks BA; Diamant YZ
Int J Fertil Menopausal Stud; 1994; 39(2):105-10. PubMed ID: 8012439
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between circulating androgens and ovarian hyperstimulation syndrome in anovulatory patients treated with hMG-hCG].
Takahashi H; Inui Y; Mimura T; Kato H; Yamano S; Oono Y; Takeuchi S; Ezaki Y; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1982 Dec; 34(12):2163-71. PubMed ID: 6818311
[TBL] [Abstract][Full Text] [Related]
17. Effect of celioscopic ovarian resection in patients with polycystic ovaries.
Campo S; Garcea N; Caruso A; Siccardi P
Gynecol Obstet Invest; 1983; 15(4):213-22. PubMed ID: 6220946
[TBL] [Abstract][Full Text] [Related]
18. Comparison between human urinary follicle-stimulating hormone and human menopausal gonadotropin treatment in polycystic ovary.
Venturoli S; Paradisi R; Fabbri R; Magrini O; Porcu E; Flamigni C
Obstet Gynecol; 1984 Jan; 63(1):6-11. PubMed ID: 6419189
[TBL] [Abstract][Full Text] [Related]
19. Vaginal progesterone administration before ovulation induction with exogenous gonadotropins in polycystic ovarian syndrome.
Buckler HM; Phillips SE; Cameron IT; Healy DL; Burger HG
J Clin Endocrinol Metab; 1988 Aug; 67(2):300-6. PubMed ID: 3134388
[TBL] [Abstract][Full Text] [Related]
20. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
